The S&P/ASX 300 Index (ASX: XKO) is relatively flat today as earnings season begins to wrap up for most companies.
At the time of writing, the ASX 300 is up 0.10% to 7,513 points. Still, just a smidgen off its all-time high record of 7,625 points reached in the middle of this month.
Nonetheless, let's take a look at which ASX 300 shares are some of the biggest movers on Tuesday.
Image source: Getty Images
Kogan.com Ltd (ASX: KGN)
The Kogan share price is steaming ahead despite no market sensitive news being released by the e-commerce company.
It appears investors are buoyant on Kogan shares after a broker weighed in their thoughts on the company last week.
Credit Suisse released a note on Thursday cutting its price target for Kogan by 7.6% to $14.06. Although this is a reduction, it's worth noting the estimate implies an upside of around 20% based on today's price.
Kogan shares are up 6.61% to $11.78 at the time of writing.
Webjet Limited (ASX: WEB)
Another mover is Webjet shares, which are advancing following a positive trading update released from the online travel agent.
The company noted that its WebBeds business returned to profitability in July, surprising the market despite current lockdowns. Furthermore, it expects WebBeds to remain profitable in the coming months.
The Webjet share price is up 3.46% to $5.69.
Appen Ltd (ASX: APX)
Following suit, Appen shares are rebounding after a heavy sell-off during the past week following its first-half results last week.
The annotated dataset provider hasn't provided any news since then, however, JPMorgan revised its outlook on Appen shares.
The broker significantly decreased its rating by 45% to $13.50. However, at the current Appen share price of $10.41, up 3.69%, this gives an upside of about 30%.
And the biggest fallers?
Mesoblast Limited (ASX: MSB)
Heading south is the Mesoblast share price after the company released a disappointing full year result for FY21.
Mesoblast reported losses across the board despite announcing significant regulatory and clinical progress for its lead product candidate, remestemcel-L.
The Mesoblast share price is down a sizeable 10.61% to $1.77.
Mercury NZ Ltd (ASX: MCY)
Also in decline, are Mercury shares despite no news coming from the company since its full year results on 17 August.
However, the energy provider received a series of broker updates from Swiss investment bank, UBS, and Australian multinational company Macquarie.
Both agencies raised their price target by 1.4% to NZ$7.30 (A$7.03), and 1% to NZ$7.27 (A$7.00), respectively.
The Mercury share price is down 5.23% to $6.52.
